Skip to content
Parakho

Sandu Pharmaceuticals Ltd

BSE 524703

Q4 FY25

Revenue
₹14.07 Cr
Profit after tax
₹0.33 Cr

As filed with the exchange, consolidated basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with BSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, consolidated basis
₹ croreQ4 FY25vs a year agoFY25
Revenue from operations14.07—67.19
Other income0.07—0.17
Total income14.14—67.36
Employee benefit expense2.83—10.92
Finance costs0.03—0.10
Depreciation & amortisation0.15—0.67
Total expenses13.80—65.20
Profit before tax0.34—2.16
Tax expense0.02—0.61
Profit after tax0.33—1.55
Total comprehensive income0.43—2.20
Earnings per share
Earnings per share, basic₹0.34₹1.60
Earnings per share, diluted₹0.34₹1.60

Q4 FY25 and FY25 — from the company’s filing with BSE. Source

Q4 FY25 results for every company Parakho holds

Why the dash

Parakho has not ingested this company’s year-ago quarter, so the change column stays empty. A dash means we do not hold the figure — never that it is zero.

Earnings call

Sandu Pharmaceuticals Ltd has not filed a concall transcript in the last 4 quarters.

Filings

12 shown · 52 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Industry

Healthcare › Pharmaceuticals

Classification as published by BSE.

Companies also in Pharmaceuticals, in alphabetical order

All 196 companies in Pharmaceuticals

Page generated from filings held to 09 Oct 2026.

Sandu Pharmaceuticals Ltd Q4 FY25 results — revenue, profit and filings · Parakho